Currently, there are 298.36M common shares owned by the public and among those 223.95M shares have been available to trade.
The company’s stock has a 5-day price change of 3.45% and -28.81% over the past three months. ABCL shares are trading -28.33% year to date (YTD), with the 12-month market performance down to -46.84% lower. It has a 12-month low price of $1.89 and touched a high of $4.34 over the same period. ABCL has an average intraday trading volume of 4.31 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.62%, -9.65%, and -22.55% respectively.
Institutional ownership of AbCellera Biologics Inc (NASDAQ: ABCL) shares accounts for 38.04% of the company’s 298.36M shares outstanding.
It has a market capitalization of $626.82M and a beta (3y monthly) value of 0.39. The earnings-per-share (ttm) stands at -$0.57. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.34% over the week and 6.32% over the month.
Analysts forecast that AbCellera Biologics Inc (ABCL) will achieve an EPS of -0.17 for the current quarter, -0.17 for the next quarter and -0.64 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.19 while analysts give the company a high EPS estimate of -0.19. Comparatively, EPS for the current quarter was -0.13 a year ago. Earnings per share for the fiscal year are expected to decrease by -13.65%, and 2.37% over the next financial year. EPS should grow at an annualized rate of -7.72% over the next five years, compared to -107.74% over the past 5-year period.
The Benchmark Company coverage for the AbCellera Biologics Inc (ABCL) stock in a research note released on February 22, 2024 offered a Buy rating with a price target of $9. Piper Sandler on their part issued Overweight rating on October 13, 2023.
